EFFECTOR Therapeutics drops IPO, taking the SPAC path with Locust Walk

eFFECTOR Therapeutics, a clinical stage biotech company co-founded by University of California Professor of 
Urology Davide Ruggero, opted out of an IPO to be aquired by Locust Walk Acquisition Corp., a Special Purpose Acquisition Company (SPAC). The deal, anticipated to close in the third quarter, includes up to $175 million in a trust and a fully committed $60 million private investment in public equity from founding series A and new investors.